109 related articles for article (PubMed ID: 7259433)
1. Cell cultures and their use in drug sensitivity prediction.
Dendy PP; Mitchell JS; Dawson A; Williamson J
Arch Geschwulstforsch; 1981; 51(1):111-8. PubMed ID: 7259433
[TBL] [Abstract][Full Text] [Related]
2. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
3. [The prediction of the individual chemosensitivity of human malignant tumors: the biological patterns and clinical results].
Chissov VI; Sergeeva NS; Borisov VI; Skotnikova OI; Sviridova IK
Eksp Klin Farmakol; 1995; 58(1):11-5. PubMed ID: 7787684
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
5. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
8. The use of in vitro methods to predict tumour response to chemotherapy.
Dendy PP
Br J Cancer Suppl; 1980 Apr; 4():195-8. PubMed ID: 6932926
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.
Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW
J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653
[TBL] [Abstract][Full Text] [Related]
11. The behaviour of tumour cells of ovarian carcinomata under in vitro conditions and the coincidence with clinical controllability of tumours.
Krafft W; Brückmann D; Brückmann J; Preibsch W; Behling H; Kademann J
Arch Geschwulstforsch; 1981; 51(1):133-8. PubMed ID: 7259435
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
13. [Anticytogram (author's transl)].
Ciuffi M
Quad Sclavo Diagn; 1979 Jun; 15 Suppl 1():662-72. PubMed ID: 400252
[TBL] [Abstract][Full Text] [Related]
14. [Studies into dependence of sensitivity of cytostatics on overlap index of ovarian cancer in cell cultures (author's transl)].
Schindler C
Zentralbl Gynakol; 1982; 104(3):156-9. PubMed ID: 7043954
[TBL] [Abstract][Full Text] [Related]
15. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
16. [Measurement of transmembrane potentials - a new method of in vitro tumor sensitivity testing].
Walliser S; Zipprich KW
Zentralbl Gynakol; 1984; 106(3):184-90. PubMed ID: 6702348
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
18. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
19. [Adjuvant chemotherapy in patients operated on for early ovarian carcinoma].
Trimbos JB; van der Burg ME
Ned Tijdschr Geneeskd; 2004 May; 148(18):874-8. PubMed ID: 15152388
[TBL] [Abstract][Full Text] [Related]
20. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]